Auris Medical Holding Ltd

NASDAQ:EARS   3:59:41 PM EDT
3.21
+0.10 (+3.06%)
Earnings Announcements

Auris Says Advancing Phase 2 Trial With AM-125 In Acute Vertigo Based On Positive Interim Data

Published: 09/17/2020 12:14 GMT
Auris Medical Holding Ltd (EARS) - Auris Medical Provides Business Update and Reports First Half 2020 Financial Results.
Auris Medical Holding Ltd - Advancing Phase 2 Trial With Am-125 in Acute Vertigo Based on Positive Interim Data.
Auris Medical Holding Ltd - Positive Outcome From Am-201 Trial in Prevention of Antipsychotic-induced Weight Gain.
Auris Medical - Addition of New Intranasal Program With Development of Drug-free Spray for Protection Against Airborne Pathogens and Allergens.
Auris Medical Holding Ltd - Review of Strategic Options Initiated.
Auris Medical Holding Ltd - Board of Directors Has Started a Process to Explore, Review and Evaluate a Broad Range of Potential Strategic Alternatives.
Auris Medical Holding Ltd - Alternatives Include Sale Or Merger of Company.